Results 101 to 110 of about 21,847 (205)

Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis. [PDF]

Blood Adv
May CJ, Trory JS, Webb CE, Walker HS, Li Y, Furniss JA, Eble JA, Poole AW, Vautrinot J, Tromans J, Hers I.   +10 more
europepmc   +1 more source

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Chen B, Qian S.
europepmc   +1 more source

Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. [PDF]

J Comput Aided Mol Des
Shahin R, Jaafreh S, Mansi I, Al Zoubi R, Abu-Irmaileh B, Azzam Y, Azzam S.   +6 more
europepmc   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]

Front Med (Lausanne)
Tu J, Wang Z, Zhang J, Xu H, Li Y, Zhang L, Gong J, Zhao L.   +7 more
europepmc   +1 more source

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025. [PDF]

Exp Hematol Oncol
Liang Y, Deng X, Wang Z, Xie C, Zheng L, Huang H, Yin S, Huang H.   +7 more
europepmc   +1 more source

Biodegradable mulch films promote sugarcane growth by regulating rhizosphere microbial communities and predicted nutrient cycling-related functional potentials. [PDF]

Front Microbiol
Duan Q, Liu Q, Mao X, Yuan Z, Pang Z, Shen Y.   +5 more
europepmc   +1 more source

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]

Cancers (Basel)
Robak T, Wolska-Washer A, Robak P.
europepmc   +1 more source

Mechanisms of resistance to BTK inhibitors independent of BTK and PLCG2 mutations

Bruton's tyrosine kinase inhibitors (BTKis) have transformed chronic lymphocytic leukemia (CLL) therapy, yet resistance remains a major challenge. While often driven by BTK or PLCG2 mutations, some resistant cases lack these alterations, and mechanisms are unclear.
openaire   +1 more source

Discovery of JH-XIII-05-01, a First-in-Class Dual IRAK1/IRAK4 Degrader for MYD88 Mutant Lymphomas. [PDF]

ACS Med Chem Lett
Hatcher JM, Liu S, Liu X, Kofides A, Canning AG, Pizzarella D, Tsakmaklis N, Guerrera ML, Patterson CJ, Guijosa A, Gokhale P, Hunter ZR, Sarosiek SR, Castillo JJ, Wang J, Buhrlage SJ, Treon SP.   +16 more
europepmc   +1 more source

„A filozófiai irodalomnak a legnehezebb könyve”

Elpis
Attila Hangai, Kosztasz Rosta
doaj   +1 more source